Physician profile
Saad Zafar
NPI 1275820706
$9,068.59
in general payments reported to CMS, 2019-2025
45 companies · $1,357 in 2025
The $1,357 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $995 · 2020: $812 · 2021: $1,655 · 2022: $1,405 · 2023: $1,502 · 2024: $1,344 · 2025: $1,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,202.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,521.36 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $866.10 | 2019-2025 | |
| Lilly USA, LLC | $675.75 | 2019-2024 | Jardiance, Mounjaro, Trulicity |
| Otsuka America Pharmaceutical, INC. | $660.99 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Braeburn INC. | $397.65 | 2023-2025 | Brixadi |
| Teva Pharmaceuticals USA, INC. | $346.16 | 2019-2025 | Austedo Xr, Austedo Xr |
| Astrazeneca Pharmaceuticals Lp | $317.47 | 2019-2025 | Breztri, Farxiga |
| Sunovion Pharmaceuticals INC. | $309.20 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $308.57 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $251.50 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.37 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $221.79 | 2019-2023 | Xifaxan |
| Vanda Pharmaceuticals INC. | $219.78 | 2019-2025 | Fanapt |
| Lundbeck LLC | $211.67 | 2019-2025 | Rexulti |
| Glaxosmithkline, LLC. | $207.00 | 2021-2024 | Trelegy Ellipta |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $192.46 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $189.85 | 2019-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $180.50 | 2019-2025 | Spravato, Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $162.62 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $157.51 | 2019-2023 | Verquvo, Belsomra |
| Sumitomo Pharma America, INC. | $134.05 | 2023-2024 | Gemtesa |
| Novo Nordisk INC | $115.86 | 2020-2023 | Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $108.92 | 2022-2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $96.49 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $87.28 | 2022-2024 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $84.68 | 2022-2023 | Quviviq |
| Indivior INC. | $82.63 | 2020-2024 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $73.03 | 2022-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $66.37 | 2019-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $65.86 | 2023-2024 | Jornay Pm |
| Abbott Laboratories | $65.45 | 2022-2024 | Freestyle Libre 2 |
| Eisai INC. | $55.21 | 2021 | |
| Amgen INC. | $51.15 | 2020-2022 | |
| Alkermes, INC. | $50.28 | 2024-2025 | Vivitrol |
| Supernus Pharmaceuticals, INC. | $48.18 | 2021-2025 | Qelbree |
| Neurocrine Biosciences, INC. | $47.78 | 2025 | |
| Avanir Pharmaceuticals, INC. | $44.61 | 2022 | |
| Amarin Pharma, INC. | $30.04 | 2021 | |
| Corium, LLC | $29.21 | 2024 | Azstarys |
| Kyowa Kirin, INC. | $21.56 | 2024 | Crysvita |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Acadia Pharmaceuticals INC | $19.31 | 2024 | Nuplazid |
| Astellas Pharma US INC | $15.76 | 2020 | |
| Shire North American Group INC | $15.00 | 2019 | |
| Neos Therapeutics, Lp | $12.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saad Zafar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.